GlaxoSmithKline Is One Of The Largest Players In The Anti-Parkinson Drugs Market, According To The Business Research Company’s Anti-Parkinson Drugs Global Market Report 2020-30: COVID-19 Growth And Change
(Companies Covered: GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc)
The global anti-Parkinson drugs market is expected to decline from $4.23 billion in 2019 to $4.12 billion in 2020 at a compound annual growth rate of -2.62%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $5.04 billion in 2023 at a compound annual growth rate of 7.01%.
Read More On The Global Anti-Parkinson Drugs Market Report At – https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report-2020-30-covid-19-growth-and-change
The anti-Parkinson drugs market consists of sales of drugs used for treating Parkinson`s disease (PD), generated by the establishments that manufacture these drugs. Parkinson`s disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body. People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems.
Global Anti-Parkinson Drugs Market Segmentation –
1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs.
2) By Route of Administration: Oral, Injection, Transdermal.
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies.
Global Anti-Parkinson Drugs Market Driver –
The increasing geriatric population and surging cases of Parkinson`s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 years.
Request For A Sample Of The Global Anti-Parkinson Drugs Market Report At – https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp
Few Points From The Global Anti-Parkinson Drugs Market TOC
1. Executive Summary
2. Anti-Parkinson Drugs Market Characteristics
3. Anti-Parkinson Drugs Market Size And Growth
3.1. Global Anti-Parkinson Drugs Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
4. Anti-Parkinson Drugs Market Segmentation
4.1. Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Anti-Parkinson Drugs Market Regional And Country Analysis
5.1. Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6. Asia-Pacific Anti-Parkinson Drugs Market
6.2. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
State: Greater London
Country: United Kingdom